Whitepapers/App Notes/Posters

Whitepaper: Drug repurposing strategies to shorten timelines

Posted: 24 November 2021 | | No comments yet

This whitepaper explores drug repurposing, where known clinical candidates or commercially approved molecules are evaluated for new targets and indications.

The high attrition rate of new chemical entities and de novo drugs in clinical phases has resulted in the rise of the R&D costs and forced the industry to look at drug repurposing or drug repositioning strategies. The obvious advantage of repurposing drug candidates is that their safety is likely to be established in certain dosages and in some delivery routes. Learn about:

  • The drug repurposing development pathway
  • The promise of repurposed drug
  • CDMO support and critical role as partners.












    To read this whitepaper in full, please complete the form below:

     









    This specialist content is provided to you free-of-charge thanks to the kind support of Thermo Fisher Scientific

    By clicking submit you confirm that you accept our terms and conditions and privacy policy.

    Send this to a friend